Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/21507| Title: | Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor Malignancies. | Austin Authors: | Sasadeusz, Joe;Grigg, Andrew P ;Hughes, Peter D;Lim, Seng Lee;Lucas, Michaela;McColl, Geoff;McLachlan, Sue Anne;Peters, Marion G;Shackel, Nicholas;Slavin, Monica;Sundararajan, Vijaya;Thompson, Alexander;Doyle, Joseph;Rickard, James;De Cruz, Peter P ;Gish, Robert G;Visvanathan, Kumar | Affiliation: | University of Western Australia, 35 Stirling Highway, Crawley, Western Australia 6009, Australia Victorian Comprehensive Cancer Centre, 305 Grattan Street, Melbourne, Victoria 3000, Australia Department of Public Health, La Trobe University, Plenty Road, Bundoora, Victoria 3086, Australia Burnet Institute, 85 Commercial Road, Melbourne, Victoria 3004, Australia The Alfred and Monash University, 85 Commercial Road, Melbourne, Victoria 3004, Australia St Vincent's Hospital, 41 Victoria Street, Fitzroy, Victoria 3065, Australia Royal Melbourne Hospital, 300 Grattan Street, Parkville, Victoria 3050, Australia University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia Peter Doherty Institute for Infection and Immunity, Elizabeth Street, Melbourne, Victoria 3000, Australia Olivia Newton-John Cancer Research Institute Ingham Institute, 1 Campbell Street, Liverpool, Sydney, North South Wales 2170, Australia University of Queensland Oral Health Centre, 288 Herston Road, Queensland 4006, Australia National University of Singapore, 21 Lower Kent Ridge Road, Singapore 119077, Singapore University of California, San Francisco, S357 Parnassus Avenue, San Francisco, CA 94143, USA Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA Austin Health |
Issue Date: | Aug-2019 | Date: | 2019-06-06 | Publication information: | Clinics in Liver Disease 2019; 23(3): 511-519 | Abstract: | Patients with malignancies require chemotherapy and other immunosuppressive therapies for treatment. Because of this immunosuppression, in patients who have ever been exposed to hepatitis B it is possible for reactivation to occur. This reactivation can be fatal. Reactivation is particularly likely in patients who receive B cell-active agents such as rituximab. The occurrence of reactivation flares may also delay further chemotherapy, which can negatively affect the outcome of the underlying malignancy. Accordingly, it is important to screen patients for markers of hepatitis B and institute antiviral prophylaxis to prevent reactivation. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/21507 | DOI: | 10.1016/j.cld.2019.04.011 | ORCID: | 0000-0002-3399-7236 |
Journal: | Clinics in Liver Disease | PubMed URL: | 31266624 | Type: | Journal Article | Subjects: | Cancer Hematological malignancy Hepatitis B Prophylaxis Reactivation Rituximab Solid tumors |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.